01—Abstract
Summary
Summary of the 8-K filed August 31, 2026. Cited figures are marked; the original filing is the authoritative source.
Incyte Corporation filed a Form 8-K on August 31, 2026 under Item 8.01 (Other Events) to disclose that it has entered into an agreement with the U.S. Centers for Medicare & Medicaid Services (CMS).
The stated aim of the agreement is to improve patient access to medicines while supporting continued U.S. biopharmaceutical innovation. Under the agreement, Incyte will enable state Medicaid programs to access Jakafi and Jakafi XR at prices aligned with those in a defined group of other advanced, industrialized nations.
The company also expects that it will not be subject to certain future CMS pricing mandates, including the proposed GUARD and GLOBE models. Incyte states that it does not expect the agreement to affect its 2026 financial guidance or to have a material impact on its future financial outlook.
02—Key points
Key Highlights
- Incyte entered into an agreement with CMS intended to improve access to medicines for American patients while supporting U.S. biopharmaceutical innovation.
- State Medicaid programs will gain access to Jakafi and Jakafi XR at prices aligned with a defined group of other advanced, industrialized nations.
- Incyte expects it will not be subject to certain future CMS pricing mandates, including the proposed GUARD and GLOBE models.
- The company does not expect the agreement to affect its 2026 financial guidance.
- The company does not expect the agreement to have a material impact on its future financial outlook.
- The disclosure is made under Item 8.01 (Other Events), indicating the company views it as a matter outside the scope of the other specific 8-K item categories.
03—Questions
Frequently Asked Questions
What did Incyte agree to with CMS?
Incyte agreed with the U.S. Centers for Medicare & Medicaid Services to enable state Medicaid programs to access Jakafi and Jakafi XR at prices aligned with those in a defined group of other advanced, industrialized nations.
Which products are affected by the agreement?
The filing names Jakafi and Jakafi XR as the products covered by the Medicaid pricing arrangement.
Does the agreement change Incyte's guidance or outlook?
Incyte states that it does not expect the agreement to affect its 2026 financial guidance or to have a material impact on its future financial outlook.
How does the agreement relate to proposed CMS pricing models?
Incyte expects that it will not be subject to certain future CMS pricing mandates, specifically the proposed GUARD and GLOBE models.
04—Continue